Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

ImmunityBio (IBRX) Consolidated Net Income (2016 - 2025)

Historic Consolidated Net Income for ImmunityBio (IBRX) over the last 12 years, with Q3 2025 value amounting to -$67.3 million.

  • ImmunityBio's Consolidated Net Income rose 2154.82% to -$67.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$348.7 million, marking a year-over-year increase of 4068.11%. This contributed to the annual value of -$413.6 million for FY2024, which is 2915.24% up from last year.
  • ImmunityBio's Consolidated Net Income amounted to -$67.3 million in Q3 2025, which was up 2154.82% from -$92.6 million recorded in Q2 2025.
  • ImmunityBio's 5-year Consolidated Net Income high stood at -$59.2 million for Q4 2024, and its period low was -$233.4 million during Q4 2023.
  • Its 5-year average for Consolidated Net Income is -$108.1 million, with a median of -$95.6 million in 2023.
  • As far as peak fluctuations go, ImmunityBio's Consolidated Net Income plummeted by 11547.37% in 2023, and later soared by 7464.63% in 2024.
  • ImmunityBio's Consolidated Net Income (Quarter) stood at -$91.6 million in 2021, then fell by 18.32% to -$108.3 million in 2022, then tumbled by 115.47% to -$233.4 million in 2023, then surged by 74.65% to -$59.2 million in 2024, then fell by 13.68% to -$67.3 million in 2025.
  • Its Consolidated Net Income was -$67.3 million in Q3 2025, compared to -$92.6 million in Q2 2025 and -$129.7 million in Q1 2025.